Tanzania to set up generic ARVs manufacturing plant

The facility which will begin commercial production of the drugs in January 2012, is expected to manufacture at least 100 million tablets every year, theeastafrican.co.ke reported.

The generic drugs will be available for a lesser price than their current price.

The news report says that the Tanzania Pharmaceutical Industries plant set up under the Trade Related Aspects of Intellectual Property Rights Agreement enables the nations that are least developed, to produce essential drugs without bringing in product patents till 2016.

Tanzania Pharmaceutical Industries, the European Commission and Action Medeor, a German medical Aid Organisation have funded the ARV plant.